A company focused on developing targeted therapies for hematologic cancers, particularly myeloproliferative neoplasms (MPNs), using computational chemistry and structural biology to create therapies for unmet medical needs.

Ajax Therapeutics

EcoR1 Capital

Boxer Capital

NYU Langone Health

Inning One Ventures

Schrödinger

Memorial Sloan - Kettering Cancer Center

Ajax Therapeutics Announces FDA Clearance of IND Application for AJ1-11095, a First-in-Class Type II JAK2 inhibitor, for the Treatment of Myelofibrosis

https://lnkd.in/gcC35a5E

Next stop->clinic for AJ-101095! (please note my COI as co-founder)

Financial Times article today about Ajax Therapeutics $95M Series C raise in support of AJ1-11095 clinical development:  

https://lnkd.in/gMPNt7U3

Ajax Therapeutics Raises $95 Million Series C Financing To Advance First-in-Class Type II JAK2 Inhibitor, AJ1-11095, Into The Clinic

– Financing led by Goldman Sachs Alternatives with participation by new investors Lilly, Vivo Capital, RA Capital Management, Point72 and existing investors – 
– AJ1-11095 will be the first Type II JAK2 Inhibitor to enter the clinic; Phase 1 study in myelofibrosis expected to begin in 2H 2024 –

https://lnkd.in/g5dJfqRM

AJAX

COM:AJAXTHERAPEUTICS

Ajax Therapeutics

locale

market

industry

website

linkedin

investor of

Metrics